Copyright
©The Author(s) 2022.
World J Clin Oncol. Apr 24, 2022; 13(4): 287-302
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.287
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.287
Region of interest | HR | P |
Sternal | 3.50 | 0.080 |
Breast ipsilateral | 1.25 | 0.048 |
Breast contralateral | 0.72 | 0.528 |
Axillary ipsilateral | 1.54 | 0.029 |
Axillary contralateral | 1.03 | 0.969 |
Combined breast/axillary/sternal | 1.27 | 0.032 |
Ratio SUVmax breast ipsilateral/ SUVmax breast contralateral | 1.34 | 0.101 |
Ratio SUVmax axillary ipsilateral/ SUVmax axillary contralateral | 1.94 | 0.027 |
Ratio SUVmax in any of breast/axillary/sternal/lowest of SUVmax breast or axillary contralateral | 1.50 | 0.036 |
- Citation: Perrin J, Farid K, Van Parijs H, Gorobets O, Vinh-Hung V, Nguyen NP, Djassemi N, De Ridder M, Everaert H. Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis. World J Clin Oncol 2022; 13(4): 287-302
- URL: https://www.wjgnet.com/2218-4333/full/v13/i4/287.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i4.287